John N. Allan, MD

Weill Cornell Medicine
Division of Hematology and Oncology
1305 York Avenue
7th Floor
New York, NY
USA 10021
1640 Hematopoietic Stem Cell Transplant in Novel Agent Era Is Associated with Improved Survival in Relapsed and Refractory Peripheral T-Cell Lymphoma
1690 Emerging Clinical Activity of REGN1979, an Anti-CD20 x Anti‑CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Follicular Lymphoma (FL), Diffuse Large B-Cell Lymphoma (DLBCL), and Other B-Cell Non-Hodgkin Lymphoma (B-NHL) Subtypes
1832 NOTCH1 Stabilization By PEST Mutations Enhances IgM-Mediated Activity in Chronic Lymphocytic Leukemia
2888 Multicenter Prospective Phase II Study of Venetoclax in Patients with Previously Treated Waldenstrom Macroglobulinemia
2970 Understanding the Differences between Clinical Trial Participants and Real-World Patients with Non-Hodgkin Lymphoma
3141 Preliminary Safety, Pharmacokinetic, and Pharmacodynamic Results from a Phase 1b/2 Dose-Escalation and Cohort-Expansion Study of the Noncovalent, Reversible Bruton's Tyrosine Kinase Inhibitor (BTKi), Vecabrutinib, in B-Lymphoid Malignancies
3142 Venetoclax As Monotherapy or in Combination: Patterns of Use and Predictors of Outcomes in an International Multicenter Study of CLL Patients
4410 Adverse Events, Patterns of Tumor Lysis Syndrome Prophylaxis and Management, and Dosing Patterns in a Large Cohort of Venetoclax Treated CLL Patients in Community and Academic Settings
4759 Treatment Patterns and Outcomes of Patients with CLL Treated with Chemoimmuno– and Novel Agent–Based Therapy: A Multicenter Study